Obinutuzumab-induced coagulopathy in chronic lymphocytic leukaemia with trisomy 12
Authors:
Open Access
- 17 June 2016
- journal article
- case report
- Published by Springer Nature in Blood Cancer Journal
- Vol. 6 (6) , e435
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumabLeukemia, 2016
- Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemiaBlood, 2016
- Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactionsBlood, 2015
- NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulationLeukemia, 2015
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting ConditionsNew England Journal of Medicine, 2014
- Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignanciesBlood, 2011
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicityBlood, 2010
- Rituximab‐induced haemorrhagic thrombocytopenia in a patient with hairy cell leukaemiaBritish Journal of Haematology, 2006